---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-005892"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:05:45.449458+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics acquires lab assets from ResearchDx for up to $6.2M, launches LucidDx Labs; CMO resigns

## Summary
- LucidDx Labs acquired licenses/assets from ResearchDx for up to $6.2M; $1.0M cash upfront, remainder contingent on license transfers and earnout.
- LucidDx Labs will operate its own CLIA/CAP lab in Lake Forest, CA to perform EsoGuard testing, replacing RDx as testing provider.
- LucidDx Labs entered a 3-year MSA with RDx for up to $1.8M in quarterly installments, plus lease at $71,465/month for lab space.
- CMO David F. Wurtman resigned effective March 31, 2022; Brian J. deGuzman, MD (current Chief Compliance Officer) will assume duties.
- Earnout payments may be made in cash or newly issued LUCD stock, not exceeding 19.99% of outstanding shares, exempt from registration.

## SEC filing metadata
- accession: 0001493152-22-005892
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315222005892/0001493152-22-005892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315222005892/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-005892
- JSON: https://secwatch.observer/filing/0001493152-22-005892.json
- Plain text: https://secwatch.observer/filing/0001493152-22-005892.txt

## Key facts
- Executive change
  David F. Wurtman resigned as Chief Medical Officer at Lucid Diagnostics Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On March 1, 2022, David F. Wurtman, M.D. resigned from his position as Chief Medical Officer of the Company, effective as of March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799011/000149315222005892/0001493152-22-005892-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.